Nucleic Acids as Novel Therapeutic Modalities to Address Multiple Sclerosis Onset and Progression

Autor: Maryam Azimi, Hussein Baharlooi, Leila Mohamed Khosroshahi, Moein Minbashi Moeini, Amir Hossein Mansourabadi
Rok vydání: 2021
Předmět:
Zdroj: Cellular and Molecular Neurobiology. 42:2611-2627
ISSN: 1573-6830
0272-4340
DOI: 10.1007/s10571-021-01158-4
Popis: The issue of treating Multiple Sclerosis (MS) begins with disease-modifying treatments (DMTs) which may cause lymphopenia, dyspnea, and many other adverse effects. Consequently, further identification and evaluation of alternative treatments are crucial to monitoring their long-term outcomes and hopefully, moving toward personalized approaches that can be translated into clinical treatments. In this article, we focused on the novel therapeutic modalities that alter the interaction between the cellular constituents contributing to MS onset and progression. Furthermore, the studies that have been performed to evaluate and optimize drugs' efficacy, and particularly, to show their limitations and strengths are also presented. The preclinical trials of novel approaches for multiple sclerosis treatment provide promising prospects to cure the disease with pinpoint precision. Considering the fact that not a single treatment could be effective enough to cover all aspects of MS treatment, additional researches and therapies need to be developed in the future. Since the pathophysiology of MS resembles a jigsaw puzzle, researchers need to put a host of pieces together to create a promising window towards MS treatment. Thus, a combination therapy encompassing all these modules is highly likely to succeed in dealing with the disease. The use of different therapeutic approaches to re-induce self-tolerance in autoreactive cells contributing to MS pathogenesis is presented. A Combination therapy using these tools may help to deal with the clinical disabilities and symptoms of the disease in the future.
Databáze: OpenAIRE
Externí odkaz: